Evidence map›Paper›PMID 37009219›Full record

ArticleiScience2023

Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation.

Jeoffrey Pelletier, Marielle Balzano, Jérôme Destin, Camille Montersino, Marjorie C Delahaye, Tony Marchand, Anne-Laure Bailly, Florence Bardin, Emilie Coppin, Armelle Goubard and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Jeoffrey PelletierAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Marielle BalzanoAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Jérôme DestinUniversity Rennes, INSERM, EFS, UMR S1236, Rennes, France.
Camille MontersinoAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Marjorie C DelahayeAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Tony MarchandUniversity Rennes, INSERM, EFS, UMR S1236, Rennes, France.
Anne-Laure BaillyAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Florence BardinAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Emilie CoppinAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Armelle GoubardAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Remy CastellanoAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Marjolein J W de BruijnDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Jasper RipDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Yves ColletteAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Patrice DubreuilAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Karin TarteUniversity Rennes, INSERM, EFS, UMR S1236, Rennes, France.
Cyril BroccardoCentre de Recherche en Cancérologie de Toulouse, INSERM UMR-1037, Université de Toulouse III Paul Sabatier, Toulouse, France.
Rudi W HendriksDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Claudine SchiffAix Marseille University, CNRS, INSERM, CIML, Marseille, France.
Norbert VeyAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Michel Aurrand-LionsAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Stéphane J C ManciniAix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Centre National de la Recherche Scientifique · FRErasmus MC · NLInserm · FRCentre de Recherche en Cancérologie de Toulouse · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell acute lymphoblastic leukemia (B-ALL) reflects the malignant counterpart of developing B cells in the bone marrow (BM). Despite tremendous progress in B-ALL treatment, the overall survival of adults at diagnosis and patients at all ages after relapse remains poor. Galectin-1 (GAL1) expressed by BM supportive niches delivers proliferation signals to normal pre-B cells through interaction with the pre-B cell receptor (pre-BCR). Here, we asked whether GAL1 gives non-cell autonomous signals to pre-BCR

Indexed as

Biological sciencesCell biologyMolecular biology

Identifiers

PMID37009219
PMCPMC10060685
OpenAlexW4323816825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.